KIT and neoplasm: For the patients with c-KIT exon 11 mutations, Incorvaia et al. have reported that 60 metastatic GIST patients with their tumor harboring deletion or insertion/deletion in codons 557 and/or 558 (D-557/8) had shorter PFS to first-line imatinib than the patients with their tumors harboring mutations other than D-557/8 [31].